Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, May 2001, p. 556-559, Vol. 8, No. 3
1071-412X/01/$04.00+0 DOI: 10.1128/CDLI.8.3.556-559.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Influence of Patient Age on Streptococcus
pneumoniae Serotypes Causing Invasive Disease
Jaime
Inostroza,1
Ana Maria
Vinet,1
Gloria
Retamal,1
Pedro
Lorca,1
Gonzalo
Ossa,1
Richard R.
Facklam,2 and
Ricardo
U.
Sorensen3,*
Immunology Laboratory and Departments of
Pediatrics and Internal Medicine, Hospital Regional de Temuco, and
the Departments of Basic Sciences, Pediatrics and Internal Medicine,
Universidad de la Frontera, Temuco, Chile1;
Laboratory Section, Childhood and Respiratory Disease Branch,
Division of Bacterial and Mycotic Diseases, National Center for
Infectious Diseases, Centers for Disease Control and Prevention,
Atlanta, Georgia2; and Department of
Pediatrics, Louisiana State University Health Sciences Center, New
Orleans, Louisiana3
Received 23 June 2000/Returned for modification 8 August
2000/Accepted 15 February 2001
 |
ABSTRACT |
All clinical S. pneumoniae specimens isolated from
patients with invasive or sterile-site infections admitted to one
regional general hospital in southern Chile were collected during a
5-year period (February 1994 to September 1999). A total of 247 strains belonging to 50 serotypes were isolated in this survey: 69 in patients
under 5 years of age, 129 in patients 5 to 64 years old, and 49 from
patients 65 years and older. Eight serotypes were identified in all age
groups, while all other serotypes were found exclusively in one age
group or in patients over 4 years of age. Serotype 3 was never found in
patients under 5 years old, and serotype 14 was not found in patients
>64 years of age. There was no difference in the serotypes causing
infection in each one of the 5 years of the survey. Our results suggest
that both bacterial virulence factors and host factors play an
important role in the selection of S. pneumoniae serotypes
causing invasive infection. Possible host factors include age-related
differences in the immune response. Comparative studies with other
areas of the world may help to further understanding of our
observations in southern Chile.
| |
INTRODUCTION |
Capsular serotypes of
Streptococcus pneumoniae causing invasive infections vary
according to geographic location and socioeconomic status of the study
population (2, 3, 11, 30, 31). Information about these
serotypes in different areas of the world is essential for the
formulation of conjugate vaccines (24).
Bacterial factors are likely to influence the selection of serotypes
causing invasive infections. When both nasopharyngeal carriage and
invasive infections have been studied in the same individual, a high
degree of correlation in serotypes has been found (9). On
the other hand, some pneumococcal serotypes found colonizing the
nasopharynx have little tendency to cause invasive disease (11,
16, 27). These observations suggest that certain pneumococcal
serotypes have characteristics that represent an advantage for
invasiveness. In addition, differences in infection-causing pneumococcal serotypes have been attributed to the emerging, worldwide antibiotic resistance of some serotypes (2, 3, 7, 13, 31).
The characteristics of the host may also contribute to serotype
selection. Underlying central nervous system and heart diseases, as
well as malignancies, are frequently identified in patients developing
invasive infections (13). Recently, human immunodeficiency virus (HIV) infections have become a major risk factor for the development of invasive pneumococcal infections (19). The
extent to which these factors select for infections with specific
serotypes is presently unknown.
Age has a clear influence on the overall incidence of invasive
infections most frequent in the first years of life (14) and also in persons older than 65 years (1). Some studies
suggest that different serotypes cause infections in different age
groups (20). We had an opportunity to explore this
possibility further in a relatively homogenous patient population
without HIV infection, where pneumococcal antibiotic resistance was not
a factor during the 5-year study period. Our results document
interesting differences in serotypes causing invasive disease at
different ages.
| |
MATERIALS AND METHODS |
Study population.
The study population consisted of patients
of all ages seeking medical care and being admitted to any of the
in-patient services of the Hospital Regional in Temuco, a city of
300,000 inhabitants in southern Chile. The low- and middle-income
populations of this city generally seek medical care from the Chilean
National Health Service at this hospital, where patients are admitted
to the internal medicine, surgery, obstetric, and pediatric services.
All samples were sent to the Central Laboratory of the hospital. Both
HIV type 1 (HIV-1) and HIV-2 serology was performed by enzyme-linked immunosorbent assay (Abbott Laboratories, Chicago, Ill.) on all patients in this study. No HIV-seropositive patients with pneumococcal infections were identified.
Sample definition and collection.
All S. pneumoniae strains from invasive infections or infections in
normally sterile sites were included in this study. Strains isolated
from blood, spinal fluid, pleural fluid, or ascitic fluid were defined
as invasive, and strains isolated from the conjunctiva, middle ear, or
sinus cavities were classified as coming from sterile sites. Clinical
isolates were collected and serotyped between February 1994 and
September 1999.
Pneumococcal serotyping.
Serotyping of S. pneumoniae strains was performed by one of us (J.I.) in the
pneumococcal serotyping laboratory at the Centers for Disease Control
and Prevention (Atlanta, Ga.). Before serotyping, cultures were
transferred to 5% sheep red cell agar plates (Difco Laboratories,
Detroit, Mich.) overnight. All serotyping results were confirmed by
Quellung test.
Antibiotic sensitivities of all strains were determined by the E-test
for penicillin, cefotaxime, and vancomycin.
| |
RESULTS |
Epidemiology.
For analysis, the study population was divided
into three age groups: under 5 years of age, 5 to 64 years old, and
over 64 years old. The total population cared for at the Temuco
Regional Hospital during the 5-year study period in each of these age
groups was as follows: <5 years, 34,631; 5 to 64 years, 248,305;
>64 years, 19,180. The yearly incidence of pneumococcal
infections per 100,000 individuals during the same period was as
follows: <5 years, 193/100,000; 5 to 64 years, 54/100,000; >64 years,
234/100,000. A separate analysis of children under 2 years of age
revealed 53 infections with a yearly incidence of 348/100,000 and 16 infections in children 2 to 4 years old with an incidence of
76/100,000. A breakdown of the data for each age group in each of the 5 study years revealed that the yearly incidence of invasive pneumococcal infections in each age group remained constant (data not shown).
Serotypes and age.
Two hundred and forty-seven S. pneumoniae strains with a total of 50 serotypes were isolated
during the entire study period (Table
1). Sixty-nine, 129, and 49 strains
causing infections in children under 5 years of age, patients 5 to 64 years old, and patients over 64 years old, respectively, were found.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Distribution of S. pneumoniae serotypes
isolated from invasive and sterile-site infections according to
agea
|
|
There was no difference in the serotypes causing infection in each of
the 5 years of the survey. A separate analysis also
revealed that there
were no differences in serotypes causing infection
between the 5- to
15- and the 16- to 64-year-old patients (data
not
shown).
In the study population as a whole, the five most frequent serotypes
were 1 with 35 isolates, 5 with 22, 3 with 19, 19F with
15, and 23F
with 13. However, the distribution was markedly different
in young
children and older patients. In children under 5 years
of age, there
were nine strains of serotype 1, eight of 5, seven
each of 6B and 23F,
six of 19F, and five of 6A, while in patients
65 years and older
serotypes 3 with seven strains, 7F with five,
and 1, 19F, and 38 with
three strains each were found most
frequently.
Only 11 serotypes were isolated in all age groups, namely, 1, 5, 6A,
6B, 7F, 12F, 15B, 15C, 19A, 19F, and 23F. All other serotypes
were
found exclusively in one or two age groups, e.g., patients
over 4 or
under 64 years
only.
Children under 5 years of age differed from patients 5 years and older.
Notably, 20 serotypes present in the other age groups
were not isolated
from the youngest group, i.e., 3, 7A, 8, 9N,
10A, 10B, 11A, 11F, 13, 16, 17F, 18F, 20, 22F, 24F, 29, 35A, 35B,
36, and 38. Of these,
serotype 3 caused of 19 infections in patients
5 years and older
(15%). Five serotypes were isolated exclusively
in the youngest age
group, i.e., 9A, 21, 28F, 31, and 34, each
causing one
infection.
Twenty-two serotypes present in the other age groups were not isolated
in patients over 64 years of age: 4, 7A, 8, 9A, 9V,
10A, 11A, 11F, 13, 14, 16, 17F, 18A, 20, 21, 23B, 23C, 24F, 28F,
31, 33F, and 34. Particularly notable was the absence of infections
with serotype 14 in
patients 64 years and older, since this serotype
was isolated from nine
infections in younger
patients.
Three serotypes were isolated exclusively from patients older than 64 years, namely, 10B, 22F, and 27, each causing one
infection.
Serotype 4 was isolated only twice, once in a child under 5 years and
once in the 5- to 64-year-old
group.
Antibiotic resistance was identified in only one clinical isolate, from
a child younger than 5 years. This was a serotype
23F strain highly
resistant to penicillin and cefotaxime but not
to vancomycin
(
8).
The estimated coverage offered by various vaccines to patients of
different age groups in this study is shown in Table
2.
Table
1 shows the serotypes included
in the 23-valent polysaccharide
vaccine and also those included in the
proposed 11-valent conjugate
vaccine. Including protection offered by
serogroup cross-reactivity,
the estimated coverage of the three
conjugate vaccines for infections
in children younger than 5 years
ranged from 72 to 78%, denoting
only a small increase in coverage
going from the heptavalent to
the 11-valent vaccine. In patients over
64 years, the coverage
from conjugate vaccine ranged from 31 to 78%.
This estimated coverage
for the 11-valent conjugate vaccine is the same
for this age group
as that estimated for the 23-valent polysaccharide
vaccine.
| |
DISCUSSION |
Epidemiology.
Our results confirm the high incidence of
pneumococcal infections in young children observed in other studies
(6, 29). A recent study of invasive infections in children
under 5 years of age in west Africa estimated that the incidence of
invasive infection was 240/100,000/year in children younger than 5 years and 554/100,000/year in children younger than 1 year
(18). Our data confirm a very sharp drop in the incidence
of invasive pneumococcal infections after 2 years of age, with an
incidence in children 2 to 4 years old only slightly higher than that
in individuals 5 to 64 years old. This may reflect the absence of
high-risk groups, i.e., children with sickle cell disease and/or HIV
infections, in our study population.
An analysis of serotypes causing infections in these different age
groups suggests that there are risk factors in young children
and in
elderly populations that may be serotype specific. Two
serotypes stand
out as representative of age differences in susceptibility
because of
their relatively high frequencies in the general population:
serotype
3, absent in young children, and serotype 14, absent
in the
elderly.
Several studies have shown that serotype 3 is a frequent isolate from
the respiratory tract (
10,
12) but an infrequent
cause of
invasive
S. pneumoniae infections in children (
17,
20,
23). In a recent study of invasive infections in children
under
5 years of age in Santiago, Chile, serotype 3 caused only
3.3% of
infections (three-pneumonias) (
15).
The absence of serotype 14 in isolates from elderly patients in our
study is surprising, since this was a common serotype
isolated from
patients over 60 years old in the United States
and New Zealand
(
4,
17).
A study in Israel also found differences in the serotypes isolated in
children under 13 years and in adults (
20) but a
distribution
of serotypes different from that found in Chile. For
example,
while serotype 6B was isolated almost exclusively in adults in
Israel, it caused 11.3% of infections in children under 2 years
of age
in
Temuco.
The relatively high frequency of infections with high-numbered
serotypes (28F to 38) in children under 5 years and in adults
over 64 years in Temuco is interesting. Serotypes 28F, 31, 33F,
34, 35F caused
11% of invasive and sterile-site infections in
children under 5 years
in Temuco. Yet none of these serotypes
is included in the conjugate
vaccines, and only serotype 33F is
included in the polysaccharide
vaccine. Nor were any of these
serotypes identified in young children
with invasive infections
in Santiago, Chile, further documenting the
importance of local
variations in serotype predominance
(
15).
Taken together, our data and those reported by others support the
notion that age plays a role in the serotypes causing infection.
Socioeconomic and geographical differences do not explain our
results
for a homogeneous patient population living in the same
geographical
area (
11). Year-to-year variation in serotype distribution
was not a factor in our study or in other studies of infections
over
time (
20,
30). Furthermore, antibiotic resistance due
to
preventive-antibiotic use in special-risk populations (
26)
and underlying immune system abnormalities such as those due to
HIV
infection (
19) were also ruled out as an explanation for
our results for different age groups. Lastly, our population was
not
immunized with any form of pneumococcal vaccine that could
have altered
the immune response and therefore the incidence of
infections with some
serotypes.
Whether or not differences in the immune response may account for some
of these observations is questionable. Transplacental
transmission of
immunoglobulin G (IgG) antibodies is very efficient
for serotypes 3 and
14 (
5), so that this is an unlikely explanation
for the
absence of serotype 3 infections and the high incidence
of serotype 14 infections in young children. Furthermore, transplacentally
transmitted
antibodies decrease rapidly during the first 6 months
of life
(
22). In patients with recurrent infections, serotype
3 is
clearly more immunogenic in children than serotype 14, while
in adults
serotype 14 induces a very high concentration of IgG
antibodies
(
25). For serotype 14 antibodies detected by enzyme-linked
immunosorbent assay also correlate well with antibody avidity
and
opsonophagocytic activity in the elderly (
21). Since
antibodies
to other serotypes have low opsonophagocytic activity in the
elderly,
our observations may be explained by the functional properties
of antibodies against pneumococcal serotypes in this age group.
However, this would not explain the high incidence of serotype
14 infection in adults in New Zealand (
17). We conclude that
age differences are probably due to multiple factors, defying
a clear
interpretation at this
point.
Our findings are relevant for prevention strategies, antibiotic usage,
and vaccine design. Current recommendations for vaccine
formulation are
based on serotypes and serogroup distribution
for invasive and
sterile-site pneumococcal infections (
24).
Conjugated
vaccines are recommended for children under 5 years
of age
(
28). If our results are confirmed in other studies,
the
age of the patient population to be immunized in different
regions of
the world will have to be considered. One important
observation is that
serotype 3, included in all conjugate vaccines,
and serotype 7F,
included in the 11-valent conjugate vaccine,
are very infrequent causes
of infections in children under 5 years
of age in Temuco, Chile.
Continued surveillance of pneumococcal
infections at different ages is
necessary to design the most-effective
vaccines to be used at the
most-appropriate
ages.
| |
ACKNOWLEDGMENTS |
We thank Terry Thompson for his advice and support in the
serotyping of streptococcal strains at the CDC and Patricia A. Giangrosso for assistance in the preparation of the manuscript.
| |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Pediatrics-LSUHSC, 1542 Tulane Ave., Box T8-1, New Orleans, LA
70112-2822. Phone: (504) 568-2578. Fax: (504) 568-7598. E-mail:
rsoren{at}lsuhsc.edu.
| |
REFERENCES |
| 1.
|
Advisory Committee on Immunization Practices.
1997.
Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Morbid. Mortal. Wkly. Rep.
46:1-24[Medline].
|
| 2.
|
Block, S. I.,
C. J. Harrison,
J. A. Hedrick,
R. D. Tyler,
R. A. Smith,
E. Keegan, and S. A. Chartrand.
1995.
Penicillin-resistant Streptococcus pneumoniae in acute otitis media: risk factors, susceptibility patterns and antimicrobial management.
Pediatr. Infect. Dis. J.
14:751-759[Medline].
|
| 3.
|
Boken, D. J.,
S. A. Chartrand,
E. S. Moland, and R. V. Goering.
1996.
Colonization with penicillin-nonsusceptible Streptococcus pneumoniae in urban and rural child-care centers.
Pediatr. Infect. Dis. J.
15:667-672[CrossRef][Medline].
|
| 4.
|
Butler, J. C.,
R. F. Breiman,
H. F. Campbell,
H. B. Lipman,
C. V. Broome, and R. R. Facklam.
1993.
Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations.
JAMA
270:1826-1831[Abstract/Free Full Text].
|
| 5.
|
Costa-Carvalho, B. T.,
M. M. Carneiro-Sampaio,
D. Solé,
C. K. Naspitz,
L. E. Leiva, and R. U. Sorensen.
1999.
Transplacental transmission of serotype-specific pneumococcal antibodies in a Brazilian population.
Clin. Diagn. Lab. Immunol.
6:50-54[Abstract/Free Full Text].
|
| 6.
|
Escola, J.,
A. K. Takala,
E. Kela,
E. Pekkanen,
R. Kalliokosi, and M. Leinonen.
1992.
Epidemiology of invasive pneumococcal infections in children in Finland.
JAMA
268:3323-3327[Abstract/Free Full Text].
|
| 7.
|
Friedland, I. R., and G. H. J. McCracken.
1994.
Management of infections caused by antibiotic-resistant Streptococcus pneumoniae.
N. Engl. J. Med.
331:337-382[Free Full Text].
|
| 8.
|
Gherardi, G.,
J. Inostroza,
M. O'Ryan,
V. Prado,
S. Prieto,
C. Arellano,
R. E. Facklam, and B. Beall.
1999.
Genotypic survey of recent  -lactam-resistant pneumococcal nasopharyngeal isolates from asymptomatic children in Chile.
J. Clin. Microbiol.
37:3725-3730[Abstract/Free Full Text].
|
| 9.
|
Gray, B. M.,
G. M. Converse, and H. C. Dillon.
1980.
Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infections during the first 24 months of life.
J. Infect. Dis.
142:923-933[Medline].
|
| 10.
|
Gray, B. M., and H. C. Dillon.
1986.
Clinical and epidemiological studies of pneumococcal infection in children.
Pediatr. Infect. Dis. J.
5:201-207.
|
| 11.
|
Inostroza, J.,
O. Trucco,
V. Prado,
A. M. Vinet,
G. Retamal,
G. Ossa,
R. R. Facklam, and R. U. Sorensen.
1998.
Capsular serotype and antibiotic resistance of Streptococcus pneumoniae isolated in two Chilean cities.
Clin. Diagn. Lab. Immunol.
5:176-180[Abstract/Free Full Text].
|
| 12.
|
Jorgensen, J. H.,
A. W. Howell,
L. A. Maher, and R. R. Facklam.
1991.
Serotypes of respiratory isolates of Streptococcus pneumoniae compared with capsular types included in the current pneumococcal vaccine.
J. Infect. Dis.
163:644-646[Medline].
|
| 13.
|
Kaplan, S. L.,
E. O. Mason,
W. J. Barson,
E. R. Wald,
M. Arditi,
T. Q. Tan,
G. E. Schutze,
J. S. Bradley,
L. B. Gicner,
K. S. Kim, and R. Yogev.
1998.
Three-year multicenter surveillance of systemic pneumococcal infections in children.
Pediatrics
102:538-545[Abstract/Free Full Text].
|
| 14.
|
Klein, J. O.
1981.
The epidemiology of pneumococcal disease in infants and children.
Rev. Infect. Dis.
3:246-253[Medline].
|
| 15.
|
Levine, M.,
R. Lagos,
O. S. Levine,
I. Heitmann,
N. Henriquez,
M. E. Pinto,
A. M. Alvarez,
E. Wu,
C. Mayorga, and A. Reyes.
1998.
Epidemiology of invasive pneumococcal infections in infants and young children in metropolitan Santiago, Chile, a newly industrializing country.
Pediatr. Infect. Dis. J.
17:287-293[CrossRef][Medline].
|
| 16.
|
Lloyd-Evans, N.,
T. J. O'Dempsey,
I. Baldeh,
O. Secka,
E. Demba,
J. E. Todd,
T. F. McArdle,
W. S. Banya, and B. M. Greenwood.
1996.
Nasopharyngeal carriage of pneumococci in Gambian children and their families.
Pediatr. Infect. Dis. J.
15:866-871[CrossRef][Medline].
|
| 17.
|
Martin, D. R., and M. S. Brett.
1996.
Pneumococci causing invasive disease in New Zealand, 1987-94: serogroup and serotype coverage and antibiotic resistances.
N. Z. Med. J.
108:288-290.
|
| 18.
|
O'Dempsey, T. J.,
T. F. McArdle,
N. Lloyd-Evans,
I. Baldeh,
B. E. Lawrence,
O. Secka, and B. Greenwood.
1996.
Pneumococcal disease among children in a rural area of west Africa.
Pediatr. Infect. Dis. J.
15:431-437[CrossRef][Medline].
|
| 19.
|
Paul, J.
1997.
HIV and pneumococcal infections in Africa.
Trans. R. Soc. Trop. Med. Hyg.
91:632-637[CrossRef][Medline].
|
| 20.
|
Rahav, G.,
Y. Toledano,
D. Engelhard,
A. Simhon,
A. E. Moses,
T. Sacks, and M. Shapiro.
1997.
Invasive pneumococcal infections. A comparison between adults and children.
Medicine
76:295-303[CrossRef][Medline].
|
| 21.
|
Romero-Steiner, S.,
D. Musher,
M. S. Cetron,
L. B. Pais,
J. E. Groover,
A. E. Fiore,
B. D. Plikaytis, and G. M. Carlone.
1999.
Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity.
Clin. Infect. Dis.
29:281-288[Medline].
|
| 22.
|
Shahid, N. S.,
M. C. Steinhoff,
S. S. Hoque,
T. Begum,
C. Thompson, and G. R. Siber.
1995.
Serum, breast milk, and infant antibody after maternal immunisation with pneumococcal vaccine.
Lancet
346:1252-1257[CrossRef][Medline].
|
| 23.
|
Shapiro, E. D., and R. Austrian.
1994.
Serotypes responsible for invasive Streptococcus pneumoniae infections among children in Connecticut.
J. Infect. Dis.
169:212-214[Medline].
|
| 24.
|
Sniadak, D. H.,
B. Schwartz,
H. Lipman,
J. Bogaerts,
J. C. Butler,
R. Dagan,
G. Echaniz-Aviles,
N. Lloyd-Evans,
A. Fenoli,
N. I. Girgis,
J. Henrichsen,
K. Klugman,
D. Lehmann,
A. K. Takala,
J. Vandepitte,
S. Gove, and R. F. Breiman.
1995.
Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children implications for vaccine strategies.
Pediatr. Infect. Dis. J.
14:503-510[Medline].
|
| 25.
|
Sorensen, R. U.,
L. E. Leiva,
F. C. Javier,
D. M. Sacerdote,
N. Bradford,
B. Butler,
P. Giangrosso, and C. Moore.
1998.
Influence of age on the response to Streptococcus pneumoniae vaccine in patients with recurrent infections and normal immunoglobulin concentrations.
J. Allergy Asthma Clin. Immunol.
102:215-221.
|
| 26.
|
Steele, R. W.,
R. Warrier,
P. J. Unkel,
B. J. Foch,
R. F. Howes,
S. Shah,
K. Williams,
S. Moore, and S. J. Jue.
1996.
Colonization with antibiotic-resistant Streptococcus pneumoniae in children with sickle cell disease.
J. Pediatr.
128:531-535[CrossRef][Medline].
|
| 27.
|
Takala, A. K.,
J. V. Varkila,
E. Tarkla,
M. Leinonen, and J. M. Musser.
1996.
Subtyping of common pediatric pneumococcal serotypes from invasive disease and pharyngeal carriage in Finland.
J. Infect. Dis.
173:128-135[Medline].
|
| 28.
|
U.S. Department of Health and Human Services.
2000.
First pneumococcal vaccine approved for infants and toddlers.
HHS News.
|
| 29.
|
Voss, L.,
D. Lennon,
K. Okesene-Gafa,
S. Ameratunga, and D. Martin.
1994.
Invasive pneumococcal disease in a pediatric population, Auckland, New Zealand.
Pediatr. Infect. Dis. J.
13:873-878[Medline].
|
| 30.
|
World Health Organization.
1993.
Programme for the control of acute respiratory infections. Pneumococcal conjugate vaccines.
In
Report of a meeting. World Health Organization, Geneva, Switzerland.
|
| 31.
|
Zenni, M. K.,
S. H. Cheatham,
J. M. Thompson,
G. W. Reed,
A. B. Batson,
P. S. Palmer,
K. L. Holland, and K. M. Edwards.
1995.
Streptococcus pneumoniae colonization in the young child: association with otitis media and resistance to penicillin.
J. Pediatr.
127:533-537[CrossRef][Medline].
|
Clinical and Diagnostic Laboratory Immunology, May 2001, p. 556-559, Vol. 8, No. 3
1071-412X/01/$04.00+0 DOI: 10.1128/CDLI.8.3.556-559.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Chang, Q., Zhong, Z., Lees, A., Pekna, M., Pirofski, L.
(2002). Structure-Function Relationships for Human Antibodies to Pneumococcal Capsular Polysaccharide from Transgenic Mice with Human Immunoglobulin Loci. Infect. Immun.
70: 4977-4986
[Abstract]
[Full Text]
Top
Abstract
Introduction
